Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.

Ran S, Mohamedali KA, Luster TA, Thorpe PE, Rosenblum MG.

Neoplasia. 2005 May;7(5):486-96.


The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.

Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG.

Neoplasia. 2005 Oct;7(10):912-20.


Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.

Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG.

Cancer Res. 2006 Nov 15;66(22):10919-28.


In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.

Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG.

Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7866-71. Erratum in: Proc Natl Acad Sci U S A 2002 Aug 6;99(16):10941.


Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.

He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K.

J Natl Cancer Inst. 2002 Jun 5;94(11):819-25.


Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.

Hsu AR, Cai W, Veeravagu A, Mohamedali KA, Chen K, Kim S, Vogel H, Hou LC, Tse V, Rosenblum MG, Chen X.

J Nucl Med. 2007 Mar;48(3):445-54.


Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis.

Chang CC, Lin MT, Lin BR, Jeng YM, Chen ST, Chu CY, Chen RJ, Chang KJ, Yang PC, Kuo ML.

J Natl Cancer Inst. 2006 Jul 19;98(14):984-95.


Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.

Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone NM.

Clin Cancer Res. 2011 Apr 15;17(8):2328-38. doi: 10.1158/1078-0432.CCR-10-2943.


Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice.

Gu JW, Young E, Busby B, Covington J, Johnson JW.

Cancer Biol Ther. 2009 Mar 15;8(6):514-21. doi: 10.4161/cbt.8.6.7689.


Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2.

Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, Cheung LH, Hittelman WN, Zhang W, Waltenberger J, Thorpe PE, Rosenblum MG.

BMC Cancer. 2011 Aug 17;11:358. doi: 10.1186/1471-2407-11-358.


The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer.

Achen MG, Williams RA, Baldwin ME, Lai P, Roufail S, Alitalo K, Stacker SA.

Growth Factors. 2002 Jun;20(2):99-107.


Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.

Zhang D, Li B, Shi J, Zhao L, Zhang X, Wang C, Hou S, Qian W, Kou G, Wang H, Guo Y.

Cancer Res. 2010 Mar 15;70(6):2495-503. doi: 10.1158/0008-5472.CAN-09-3488.


Multiplexed PET probes for imaging breast cancer early response to VEGF₁₂₁/rGel treatment.

Yang M, Gao H, Sun X, Yan Y, Quan Q, Zhang W, Mohamedali KA, Rosenblum MG, Niu G, Chen X.

Mol Pharm. 2011 Apr 4;8(2):621-8. doi: 10.1021/mp100446t.


VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms.

Schoeffner DJ, Matheny SL, Akahane T, Factor V, Berry A, Merlino G, Thorgeirsson UP.

Lab Invest. 2005 May;85(5):608-23.


Expression of vascular endothelial growth factor and receptor flk-1 in colon cancer liver metastases.

Cheng J, Slavin RE, Gallagher JA, Zhu G, Biehl TR, Swanstrom LL, Hansen PD.

J Hepatobiliary Pancreat Surg. 2004;11(3):164-70.


Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.

Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, Lonning S, McPherson J, Yingling JM, Biswas S, Mundy GR, Reiss M.

Mol Cancer. 2010 May 26;9:122. doi: 10.1186/1476-4598-9-122.


Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action.

Wang S, Liu Q, Zhang Y, Liu K, Yu P, Liu K, Luan J, Duan H, Lu Z, Wang F, Wu E, Yagasaki K, Zhang G.

Mol Cancer. 2009 Oct 1;8:81. doi: 10.1186/1476-4598-8-81.

Items per page

Supplemental Content

Support Center